scholarly journals Immune Response Targeting Sjögren’s Syndrome Antigen Ro52 Suppresses Tear Production in Female Mice

2018 ◽  
Vol 19 (10) ◽  
pp. 2935 ◽  
Author(s):  
Marta Trzeciak ◽  
Harini Bagavant ◽  
Joanna Papinska ◽  
Umesh Deshmukh

Autoantibodies reactive against Ro52 are present in 70% of Sjögren’s syndrome patients and are associated with higher disease severity. However, their role in causing aqueous deficient dry eye, a major cause for morbidity in Sjögren’s syndrome, is unclear. To investigate whether immune responses targeting Ro52 contribute towards the dry eye, male and female NZM2758 mice were immunized with recombinant Ro52. Tear production was measured by the phenol red thread test. Sera were analyzed for anti-Ro52 levels by immunoprecipitation. Lacrimal glands were evaluated for inflammatory foci and IgG deposits. Our results showed that, although all mice generated anti-Ro52 antibodies, only females developed a significant drop in tear production. None of the mice developed severe lacrimal gland inflammation, and female mice with anti-Ro52 showed higher levels of IgG deposits within their glands. Passive transfer of anti-Ro52 sera caused reduced tear production in female mice, but not in males. This study demonstrates for the first time that immune responses initiated by Ro52 induce aqueous dry eye, and this may be driven by anti-Ro52 antibodies. Furthermore, the sexual dimorphism in glandular dysfunction suggests that the lacrimal glands in females are more susceptible to autoantibody-mediated injury.

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 129
Author(s):  
Min Song ◽  
Jide Tian ◽  
Blake Middleton ◽  
Cuong Q. Nguyen ◽  
Daniel L. Kaufman

Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltrates in the salivary and lachrymal glands resulting in oral and ocular dryness. There are no clinically approved therapies to slow the progression of SS. Immune cells possess receptors for the neurotransmitter GABA (GABA-Rs) and their activation has immunoregulatory actions. We tested whether GABA administration has potential for amelioration of SS in NOD.B10-H2b and C57BL/6.NOD-Aec1Aec2 mice, two spontaneous SS models. Oral GABA treatment was initiated (1) after the development of sialadenitis but before the onset of overt symptoms, or (2) after the appearance of overt symptoms. When assessed weeks later, GABA-treated mice had greater saliva and tear production, as well as quicker times to salvia flow, in both SS mouse models. This was especially evident when GABA treatment was initiated after the onset of overt disease. This preservation of exocrine function was not accompanied by significant changes in the number or area of lymphocytic foci in the salivary or lachrymal glands of GABA-treated mice and we discuss the possible reasons for these observations. Given that GABA-treatment preserved saliva and tear production which are the most salient symptoms of SS and is safe for consumption, it may provide a new approach to help ameliorate SS.


2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Hadas Ben-Eli ◽  
Nir Gomel ◽  
Doron Jacob Aframian ◽  
Rania Abu-Seir ◽  
Riki Perlman ◽  
...  

Author(s):  
Esen Karamursel Akpek ◽  
Kristina B. Lindsley ◽  
Rohit S. Adyanthaya ◽  
Ramya Swamy ◽  
Alan N. Baer ◽  
...  

2002 ◽  
Vol 966 (1) ◽  
pp. 223-225 ◽  
Author(s):  
TOMO SUZUKI ◽  
DEBRA A. SCHAUMBERG ◽  
BENJAMIN D. SULLIVAN ◽  
MENG LIU ◽  
STEPHEN M. RICHARDS ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document